YM 337

Drug Profile

YM 337

Alternative Names: SMART anti-platelet antibody

Latest Information Update: 04 May 2004

Price : $50

At a glance

  • Originator PDL BioPharma; Yamanouchi
  • Class Antiplatelets; Monoclonal antibodies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Stroke; Thrombosis

Most Recent Events

  • 04 May 2004 YM 337 is available for licensing (http://www.yamanouchi.com)
  • 01 Mar 2004 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
  • 01 Mar 2004 Discontinued - Phase-II for Coronary artery restenosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top